# Amgen Inc. (AMGN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AMGN
## Company Profile
- Ticker: AMGN
- Exchange: NASDAQ
- Sector: Generics, Biopharma, Oncology, Immunotherapy
- Location: Thousand Oaks, California
- Tags: Immunotherapy, Generics, Oncology, Rare Disease
## Stock Data
- Close: 414.3 USD
- Market cap: 177164638023.24 USD
- Last updated: 2026-08-11
## Business Overview
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
## Why The Stock Is Moving

As of Aug 11, 2026, AMGN closed down 0.70% at $414.30. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is a global biotechnology company with substantial U.S. and international revenue exposure. Its profile is shaped by scale, commercialization, and a broad therapeutic footprint.

## Business Model

Amgen uses commercial cash flow to fund R&D and business development across both mature and newer franchises. Investors tend to watch launch execution, regulatory events, and portfolio refresh rather than pure clinical-stage binary risk.

## Landscape Position

Amgen is one of the best-known large-cap biotech names and usually trades with less single-asset dependence than smaller peers. It still moves on pipeline, regulatory, and label milestones, but its diversified base makes the story more durable.

## Future Catalysts

- Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- No recent company news available.